Infectious Disorders - Drug Targets
Title: Editorial [ Infectious Diseases: What is in our future? ]
Volume: 7 Issue: 1
Author(s): Robert C. Goldman
Affiliation:
Export Options
About this article
Cite this article as:
Goldman C. Robert, Editorial [ Infectious Diseases: What is in our future? ], Infectious Disorders - Drug Targets 2007; 7 (1) . https://dx.doi.org/10.2174/187152607780090676
DOI https://dx.doi.org/10.2174/187152607780090676 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
19
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alzheimer's Disease and Chinese Medicine as a Useful Alternative Intervention Tool: A Mini-Review
Current Alzheimer Research The p53 Pathway Encounters the MicroRNA World
Current Genomics Circulating Exosomes as Potential Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design New Strategies in Drug Development Focusing on the Anti-Protease- Protease Balance in Alpha-1 Antitrypsin Deficiency
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Understanding the Immune and Inflammatory Response to Rhinoviruses: Recent Advances with Relevance to Asthma
Current Respiratory Medicine Reviews Current Management of Fetal and Neonatal Renal Tumors
Current Pediatric Reviews Insulin Decreases Therapeutic Efficacy in Colon Cancer Cell Line HT29 Via the Activation of the PI3K/Akt Pathway
Current Drug Discovery Technologies Surface Antigens/Receptors for Targeted Cancer Treatment: The GnRH Receptor / Binding Site for Targeted Adenocarcinoma Therapy
Current Cancer Drug Targets Misfolding of Apoprotein B-100, LDL Aggregation and 17-β -estradiol in Atherogenesis
Current Medicinal Chemistry Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy
Current Medicinal Chemistry Immunokinases, a Novel Class of Immunotherapeutics for Targeted Cancer Therapy
Current Pharmaceutical Design 4-Anilino-3-quinolinecarbonitriles: An Emerging Class of Kinase Inhibitors - An Update
Medicinal Chemistry Reviews - Online (Discontinued) Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors in Cancer
Current Drug Targets New Emerging Trends in Protein and Peptide Based Therapeutic Approaches – Part I
Current Protein & Peptide Science Mitochondrial Drug Targets in Cell Death and Cancer
Current Pharmaceutical Design A Review of IGF1 Signaling and IGF1-related Long Noncoding RNAs in Chemoresistance of Cancer
Current Cancer Drug Targets Differential Gene Expression of BRCA1, ERBB2 and TP53 Biomarkers between Human Breast Tissue and Peripheral Blood Samples of Breast Cancer Patients
Anti-Cancer Agents in Medicinal Chemistry Challenges in Lung Cancer Approaches: from the Clinical Issues to the Novel Therapies
Recent Advances in DNA & Gene Sequences (Discontinued) Chronopharmaceuticals: Hype or Future of Pharmaceutics
Current Pharmaceutical Design Editorial [Hot Topic: Perspectives in Integrin Blocking (Executive Editor: C. Marcinkiewicz)]
Current Pharmaceutical Design